- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Article
New acne drug battles bacterial resistance
Chicago - A new acne drug under development shows promise of efficacyand does not produce resistance in bacteria that causes the condition. Thenews comes at a time when the bacterium P. acnes demonstrated resistanceto traditional treatment antibiotics tetracycline and erythromycin.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
The Future of laBCC Treatment with Vishal Patel, MD, FAAD, FACMS
Prior and Current Treatments for Patients With GPP
Recognizing the Flares and Triggers of GPP
Balancing Safety and Progress in Pediatric AD
Safety Considerations for IL-17 Inhibitors
Selecting and Dosing IL-17 Inhibitors in Psoriasis
Key Takeaways on GEP Testing in Melanoma and SCC
De-Escalating Treatment Plans With Gene Expression Profiling in an 80-Year-Old Man With SCC
Switching from Biologics to JAK Inhibitors in Nonresponders and Dose Escalation
Balancing Education and Reassurance: Guiding Parents Through the Safety Profile of New Therapies
Related Content
